Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jun 26, 2014
Boston Scientific welcomes the National Institute for Health and Care Excellence (NICE) guidance on the use of implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy...
-
Jun 26, 2014
Boston Scientific welcomes the National Institute for Health and Care Excellence (NICE) guidance on the use of implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy...
-
Jun 26, 2014
Boston Scientific begrüßt die neuen Leitlinien des „National Institute for Health and Care Excellence“ (NICE) zum Einsatz von implantierbaren Kardioverter-Defibrillatoren (ICD) und Geräten...
-
Jun 14, 2014
Un video, resumen el congreso EuroPCR, que incluye los últimos resultados de los estudios clínicos EVOLVE y REPRISE II presentados por Dr. Kieth Oldroyd y Dr Daniel Blackman. Exención de...
-
Jun 14, 2014
Un breve video che racconta il congresso EuroPCR 2014, compresi gli ultimi dati clinici dagli studi EVOLVE e REPRISE II, presentati dal Dr. Keith G. Oldroyd e dal Dr. Daniel Blackman. ATTENZIONE:...
-
Jun 14, 2014
Un breve video che racconta il congresso EuroPCR 2014, compresi gli ultimi dati clinici dagli studi EVOLVE e REPRISE II, presentati dal Dr. Keith G. Oldroyd e dal Dr. Daniel Blackman.
-
Jun 13, 2014
In einer kurzen Video-Zusammenfassung zum EuroPCR-Kongress präsentieren Dr. Keith G. Oldroyd und Dr. Daniel Blackman die neuesten klinischen Daten der EVOLVE- und REPRISE-II-Studie....
-
Jun 13, 2014
A short video summary of EuroPCR2014, including the latest clinical data from the EVOLVE and REPRISE II studies, presented by Dr Keith G. Oldroyd and Dr Daniel Blackman. DISCLAIMER: Please be...
-
Jun 13, 2014
A short video summary of EuroPCR2014, including the latest clinical data from the EVOLVE and REPRISE II studies, presented by Dr Keith G. Oldroyd and Dr Daniel Blackman.
-
Jun 13, 2014
In einer kurzen Video-Zusammenfassung zum EuroPCR-Kongress präsentieren Dr. Keith G. Oldroyd und Dr. Daniel Blackman die neuesten klinischen Daten der EVOLVE- und REPRISE-II-Studie....
-
Jun 12, 2014Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent...
-
Jun 11, 2014Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent...
-
Jun 11, 2014Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent...
-
Jun 11, 2014Data Presented at the 18th International Congress of Parkinson's Disease and Movement Disorders Demonstrate Highly Significant Improvement in Motor Function for Patients with Parkinson's Disease
Patients with Parkinson's disease (PD) treated with the Boston Scientific Corporation (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System demonstrated a highly significant and consistent...
-
Jun 11, 2014Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
-
Jun 10, 2014Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
-
Jun 10, 2014Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
-
Jun 10, 2014Data Presented at the International Congress of Parkinson's Disease and Movement Disorders Demonstrate Superior Therapeutic Window for the Treatment of Parkinson's Disease
A new study has demonstrated a therapeutic advantage for a unique and innovative capability of the Boston Scientific (NYSE: BSX) Vercise™ Deep Brain Stimulation (DBS) System for the treatment of...
-
Jun 4, 2014
Boston Scientific Corporation (NYSE: BSX) has initiated the RESPOND Post Market Registry to assess real world performance of the Lotus™ Valve System. The RESPOND Registry will collect data on...
-
May 29, 2014I dati dello studio EVOLVE presentati nell'ambito dell’EuroPCR 2014 hanno dimostrato un eccellente profilo di sicurezza
Boston Scientific Corporation (NYSE: BSX) ha riportato dati positivi di follow-up a tre anni dello studio clinico EVOLVE, che confronta la sicurezza e la performance di SYNERGY™, stent...
-
May 27, 2014Solo l'1,1% dei pazienti ha manifestato rigurgito aortico paravalvolare moderato; non si sono verificati casi severi
Con un'ulteriore conferma della sua tecnologia avanzata per l'impianto transcatetere della valvola aortica (TAVI), il dispositivo Lotus?, di Boston Scientific Corporation (NYSE: BSX), continua a...
-
May 22, 2014Los datos del estudio EVOLVE, presentados hoy en EuroPCR 2014, muestran además un excelente perfil de seguridad.
Boston Scientific Corporation (NYSE: BSX) ha anunciado datos de seguimiento a los tres años del estudio clínico EVOLVE, en el que se comparan la eficacia y el rendimiento del stent coronario...
-
May 22, 2014Only 1.1 Percent of Patients Experienced Moderate Paravalvular Aortic Regurgitation; No Severe Cases Occurred
Further validating its advanced transcatheter aortic valve implantation (TAVI) technology, the Boston Scientific Corporation (NYSE: BSX) Lotus™ Valve System continued to demonstrate impressive...
-
May 21, 2014Die Daten der EVOLVE-Studie, die heute im Rahmen der EuroPCR präsentiert wurden, belegen außerdem ein exzellentes Sicherheitsprofil
Boston Scientific Corporation (NYSE: BSX) hat positive Dreijahres-Daten aus der klinischen Studie EVOLVE präsentiert, in der Sicherheit und Leistung des Everolimus freisetzenden und mit...